IL148339A0 - Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive - Google Patents

Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Info

Publication number
IL148339A0
IL148339A0 IL14833900A IL14833900A IL148339A0 IL 148339 A0 IL148339 A0 IL 148339A0 IL 14833900 A IL14833900 A IL 14833900A IL 14833900 A IL14833900 A IL 14833900A IL 148339 A0 IL148339 A0 IL 148339A0
Authority
IL
Israel
Prior art keywords
drospirenone
ethinylestradiol
contraceptive
pharmaceutical combination
daily dosage
Prior art date
Application number
IL14833900A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL148339(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL148339A0 publication Critical patent/IL148339A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14833900A 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive IL148339A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38627499A 1999-08-31 1999-08-31
EP99202826 1999-08-31
PCT/IB2000/001213 WO2001015701A1 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Publications (1)

Publication Number Publication Date
IL148339A0 true IL148339A0 (en) 2002-09-12

Family

ID=26153359

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14833900A IL148339A0 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Country Status (26)

Country Link
EP (4) EP1598069B1 (sh)
JP (2) JP4354667B2 (sh)
KR (2) KR100857344B1 (sh)
AT (3) ATE254464T1 (sh)
AU (4) AU780330B2 (sh)
BG (1) BG66114B1 (sh)
BR (1) BR0014159A (sh)
CY (3) CY1108990T1 (sh)
CZ (1) CZ300514B6 (sh)
DE (5) DE60042089D1 (sh)
DK (3) DK1380301T3 (sh)
EE (1) EE05128B1 (sh)
ES (3) ES2211580T3 (sh)
HK (3) HK1047247B (sh)
HR (1) HRP20070188B1 (sh)
HU (1) HU227207B1 (sh)
IL (1) IL148339A0 (sh)
ME (2) ME00329B (sh)
NO (1) NO326860B1 (sh)
NZ (1) NZ517845A (sh)
PL (1) PL199028B1 (sh)
PT (3) PT1598069E (sh)
RS (3) RS50262B (sh)
SI (3) SI1380301T1 (sh)
TW (1) TWI276436B (sh)
WO (1) WO2001015701A1 (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
DE60113809T2 (de) * 2000-01-18 2006-06-22 Schering Ag Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
AU2002222387A1 (en) * 2000-12-20 2002-07-01 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
MEP35908A (en) * 2002-04-26 2011-02-10 Bayer Schering Pharma Ag Treatment of hypertension in women receiving hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
WO2005087194A1 (en) * 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
EP1871363A4 (en) * 2005-03-30 2009-01-21 Genpharm Inc COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1900359A1 (en) * 2006-09-16 2008-03-19 KAIROSmed GmbH Oral modified release formulations containing drospirenon and 8-prenylnaringenin for use in female contraception
WO2008031631A2 (en) * 2006-09-16 2008-03-20 Bayer Schering Pharma Aktiengesellschaft Oral modified release formulations
UY31010A1 (es) * 2007-04-05 2008-11-28 Bayer Schering Pharma Ag Nuevo régimen de drospirenona/17b-estradiol, producto farmacéutico combinado y conjunto de elementos (kit) para su aplicacion
HUP0700826A3 (en) 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
TW200946542A (en) * 2008-03-10 2009-11-16 Vladimir Hanes New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009112231A2 (en) * 2008-03-10 2009-09-17 Schuermann Rolf New drospirenone/17beta-estradil regimen, pharmaceutical combination product and kit for performing this regimen
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
WO2011128336A1 (en) * 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Very low-dosed solid oral dosage forms for hrt
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
IT202100008834A1 (it) 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
WO2023165988A1 (en) * 2022-03-01 2023-09-07 Chemo Research, S.L. Chewable oral contraceptive

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3051168C2 (de) * 1979-01-24 1998-08-27 Minnesota Mining & Mfg Mono- bzw. Polycarbonsäureester oder deren Gemische oder Ester bzw. deren Gemische aus Isocyanaten und fluor- bzw. chlorhaltigen aliphatischen Alkoholen
DE3051166C2 (en) 1980-06-11 1990-10-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Compsns. for contraception or treatment of gynaecological disorders
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3682130D1 (de) * 1985-07-15 1991-11-28 Japan Res Dev Corp Verfahren zur herstellung von ultrafeinen organischen verbindungen.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
ZA939566B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for dry blend compression od medicaments.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
PT782449E (pt) * 1994-09-22 2003-07-31 Akzo Nobel Nv Processo de fabrico de unidades de dosagem por granulacao humida
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
ATE271386T1 (de) * 1996-07-26 2004-08-15 Wyeth Corp Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
WO1998004268A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Oral contraceptive
AU3888697A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Progestin/estrogen oral contraceptive
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
DK1380301T3 (da) * 1999-08-31 2009-04-20 Bayer Schering Pharma Ag Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel
DE60113809T2 (de) * 2000-01-18 2006-06-22 Schering Ag Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie

Also Published As

Publication number Publication date
NO20020801L (no) 2002-04-26
ME00329B (me) 2011-05-10
ATE254464T1 (de) 2003-12-15
DE122009000006I1 (de) 2009-05-07
CY1108990T1 (el) 2014-02-12
EP1598069A3 (en) 2006-04-05
DE60006692T2 (de) 2004-09-23
CY1109252T1 (el) 2014-07-02
EP1598069A2 (en) 2005-11-23
ES2211580T3 (es) 2004-07-16
CZ300514B6 (cs) 2009-06-03
JP4354667B2 (ja) 2009-10-28
AU780330B2 (en) 2005-03-17
DE122009000007I1 (de) 2009-05-07
HUP0202500A2 (en) 2002-10-28
HU227207B1 (en) 2010-11-29
HK1047247A1 (en) 2003-02-14
ES2319750T3 (es) 2009-05-12
PT1380301E (pt) 2009-03-30
CZ2002615A3 (cs) 2002-08-14
KR101019361B1 (ko) 2011-03-07
ATE429231T1 (de) 2009-05-15
JP2003508441A (ja) 2003-03-04
KR20070067248A (ko) 2007-06-27
DE122009000006I2 (de) 2012-03-22
PL199028B1 (pl) 2008-08-29
EE200200110A (et) 2003-06-16
RS50262B (sr) 2009-07-15
PT1214076E (pt) 2004-04-30
DK1214076T3 (da) 2004-02-23
CY2009015I1 (el) 2014-02-12
EP1380301B1 (en) 2009-01-14
KR100857344B1 (ko) 2008-09-05
AU2005202046B9 (en) 2008-12-11
HRP20070188B1 (hr) 2015-06-19
EP2044941A1 (en) 2009-04-08
AU2005202046A1 (en) 2005-06-09
BG66114B1 (bg) 2011-05-31
HK1047247B (zh) 2004-07-23
EP1214076B1 (en) 2003-11-19
EP1380301A1 (en) 2004-01-14
HRP20070188A2 (en) 2007-07-31
PL354406A1 (en) 2004-01-12
NZ517845A (en) 2004-12-24
HK1061968A1 (en) 2004-10-15
RS20090134A (en) 2009-11-10
DE122009000007I2 (de) 2011-07-21
KR20020040798A (ko) 2002-05-30
RS50262B2 (sr) 2018-10-31
SI1598069T1 (sl) 2009-10-31
AU2009200247A1 (en) 2009-02-19
NO326860B1 (no) 2009-03-02
ATE420648T1 (de) 2009-01-15
SI1380301T1 (sl) 2009-06-30
SI1214076T1 (en) 2004-06-30
MEP36008A (en) 2011-02-10
AU2005202046B2 (en) 2008-11-20
AU6589500A (en) 2001-03-26
AU2009200247B2 (en) 2010-07-01
DK1598069T3 (da) 2009-07-06
CY2009015I2 (el) 2014-02-12
DE60041421D1 (de) 2009-03-05
NO20020801D0 (no) 2002-02-19
YU14502A (sh) 2006-01-16
EE05128B1 (et) 2009-02-16
DE60006692D1 (de) 2003-12-24
WO2001015701A1 (en) 2001-03-08
AU2010226924A1 (en) 2010-10-28
DK1380301T3 (da) 2009-04-20
EP1598069B1 (en) 2009-04-22
ES2325589T3 (es) 2009-09-09
HUP0202500A3 (en) 2004-04-28
EP1214076A1 (en) 2002-06-19
JP2009143959A (ja) 2009-07-02
TWI276436B (en) 2007-03-21
DE60042089D1 (de) 2009-06-04
HK1082432A1 (en) 2006-06-09
BR0014159A (pt) 2002-05-07
PT1598069E (pt) 2009-07-20

Similar Documents

Publication Publication Date Title
HK1082432A1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
RU2005140938A (ru) Дроспиренон для гормональной заместительной терапии
DE69804918D1 (de) Sehr niedrigdosiertes orales Kontrazeptiv mit weniger Menstruationsblutungen und verzögerter Wirkung
AP2001002054A0 (en) Use of biogenic estrogen sulfamates for hormone replacement therapy.
CA1300017C (en) Composition for preventing osteoporosis
AU692155B2 (en) Method and composition for treatment of osteoporosis
TW200640468A (en) Pharmaceutical product for oral contraception
WO2006036055A3 (en) Method of female contraception and kit for use in such method

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed